| Methods |
1‐week washout; 2‐week placebo run‐in; inclusion criteria= sitting DBP 95‐115 mm Hg after run‐in; 8‐week double‐blind treatment |
| Participants |
Valsartan 80 mg: n=137(65 males,72 females); mean age=53.1(12.4) years; baseline sitting SBP=161.7(11.6) mm Hg, DBP=101.2(4.5) mm Hg;
Enalapril 20 mg: n=69(40 males,29 females); mean age=52.5(10.3) years; baseline sitting SBP=161.5(10.4) mm Hg, DBP=102.2(4.2) mm Hg;
Placebo: n=142(76 males,66 females); mean age=53.1(12.9) years; baseline sitting SBP=161.0(11.5) mm Hg, DBP=101.8(4.4) mm Hg |
| Interventions |
Valsartan 80 mg once daily;
Enalapril 20 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from Table 3, p. 1150; Jadad score=3; funding source= Ciba‐Geigy |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
